Jun. 27 at 1:37 PM
$PHIO I expect that the Renmark Conference on June 30, 2025, is to announce PHIO inking a deal with an undisclosed US based CDMO for sd-RNAi manufacture. I suspect that it is Nitto Avecia. PHIO will take on up front fees perhaps
$500,000 to
$1,000,000, some of which will be reflected in the next reporting period.
We may get further disclosure on the deal after cohort 5, if Phase 1b is determined to be successful. A Phase2b-Phase3, implemented perhaps as early as late Q2 2026, will require significant manufacture of INTASYL. It is critical to begin process transfer and validation runs well before Q2 2026.
Obviously PHIO management is confident in cohort results to date, to commit upfront fees to begin to map out its commercialization strategy.
Hopefully dilution will occur at much higher levels.
Godspeed.
